Skip to main content
MedinCell S.A. logo

MedinCell S.A. — Investor Relations & Filings

Ticker · MEDCL ISIN · FR0004065605 LEI · 969500R79U6PXCL2FF46 PA Manufacturing
Open in API
Filings indexed 522 across all filing types
Latest filing 2022-09-05 Capital/Financing Update
Country FR France
Listing PA MEDCL

About MedinCell S.A.

https://www.medincell.com/en/

MedinCell S.A. is a pharmaceutical company at the commercial stage that specializes in the development of long-acting injectable (LAI) therapies. The company's core is its proprietary BEPO® technology platform, which enables the controlled and sustained release of active pharmaceutical ingredients over periods ranging from days to months after a single injection. This technology forms a fully biodegradable depot in situ, designed to improve treatment efficiency, enhance patient compliance, and increase the global accessibility of medicines. MedinCell develops a portfolio of LAI products across various therapeutic areas, including psychiatry, advancing its pipeline through both internal research and strategic partnerships with other pharmaceutical organizations.

Recent filings

Filing Released Lang Actions
Inside Information / Other news releases
Capital/Financing Update Classification · 99% confidence The document is a press release dated September 5, 2022, announcing that MedinCell has secured a new credit facility of 40 million euros from the European Investment Bank (EIB). The core subject matter is a financing agreement, including details on tranches, repayment terms, and associated warrants. This directly relates to the company's fundraising and capital structure activities. Based on the provided definitions, the most appropriate classification is 'Capital/Financing Update' (CAP). It is not a full Annual Report (10-K), an Earnings Release (ER), or a general Regulatory Filing (RNS), as the content is highly specific to a financing event.
2022-09-05 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is a press release dated August 29, 2022, announcing a significant development: Teva Pharmaceuticals is launching a Phase 3 study for mdc-TJK, which triggers a $3 million payment to MedinCell. This type of announcement, detailing a specific corporate event (a clinical trial milestone payment and initiation), is characteristic of an Earnings Release (ER) if it were quarterly results, or more generally, a significant corporate update. Since it is not a full financial report (10-K or IR), a transcript (CT), or a management discussion (MDA), and it announces a specific financial/development milestone, it fits best as an Earnings Release (ER) which often includes key operational and financial highlights outside of the formal quarterly filing, or potentially a Regulatory Filing (RNS) if it were less specific. Given the focus on a clinical trial milestone and associated payment, it is a key operational update. However, looking at the definitions, 'ER' is for initial announcement of periodical financial results (key highlights only). This is a specific operational/partnership update. Since it is a formal press release announcing a major corporate event (clinical trial advancement and payment), and it doesn't fit perfectly into the other specific categories like CAP (financing) or LTR (legal), it is most appropriately classified as a general Regulatory Filing (RNS) or potentially an Earnings Release (ER) if we interpret 'key highlights' broadly to include major operational news. Given the structure and content (press release format, contact info, forward-looking statements disclaimer), it strongly resembles an announcement that would accompany or precede formal filings. Since it is not a formal financial report, and it is a specific corporate announcement, RNS (Regulatory Filings - general regulatory announcements and fallback) is a strong candidate. However, many companies use press releases for major operational milestones that impact future earnings, making ER plausible. Since it is not explicitly about quarterly financial results but about a partnership milestone, RNS is the safer fallback for a non-standard announcement. Let's re-evaluate: It announces a development milestone and a payment. This is often included in an ER or a specific operational update. Since there is no specific category for 'Clinical Trial Milestone Announcement', RNS is the most appropriate fallback for a significant, non-periodic regulatory/corporate announcement not covered elsewhere.
2022-08-29 French
Inside Information / Other news releases
Regulatory Filings Classification · 95% confidence The document is a press release dated August 29, 2022, announcing a significant business development: Teva Pharmaceuticals initiating a Phase 3 clinical trial for a product using MedinCell's technology, and MedinCell receiving a milestone payment. This type of announcement, detailing operational progress, partnerships, and immediate financial implications outside of standard periodic financial reporting (like 10-K or IR), is characteristic of an Earnings Release (ER) or a general regulatory announcement. Since it focuses on a specific, material business event rather than comprehensive quarterly results (ER) or a general regulatory filing fallback (RNS), and it is not a transcript, presentation, or formal report, it fits best as an Earnings Release (ER) which often includes key operational highlights alongside financial context, or potentially RNS if it's a mandatory disclosure. Given the structure (headline, key updates, boilerplate 'About Us', contacts, forward-looking statements), it strongly resembles an Earnings Release (ER) or a major corporate update. However, since it is not explicitly labeled as 'Earnings' but rather a 'Phase 3 study initiation' and milestone payment, and it is a formal announcement, the most appropriate general category for material, non-periodic corporate news that isn't a specific report type is often RNS (Regulatory News Service/General Regulatory Filing). Given the options, and that it's a press release announcing a major development, RNS is the safest general classification if ER is reserved strictly for quarterly/annual results summaries. Since it contains key financial/operational highlights, ER is plausible, but RNS covers general material announcements well. I will lean towards RNS as the most encompassing category for non-standard, material press releases, although ER is a close second if this is considered an 'event-driven' earnings-like update.
2022-08-29 English
Inside Information / Other news releases
Environmental & Social Information Classification · 99% confidence The document is titled 'MedinCell publishes its 2021-2022 ESG annual report' and explicitly discusses the content of this ESG report, including objectives, extra-financial data, and a quote about its commitment. The key phrase is the publication of the 'ESG annual report'. This directly corresponds to the definition of Environmental & Social Information (SR). Although it is an announcement about the report, the content provided is substantial enough to be classified as the report information itself, rather than just a brief 'Report Publication Announcement' (RPA), especially given the detailed context and length (6819 chars). The primary subject matter is ESG performance.
2022-08-17 English
Informations privilégiées / Autres communiqués
Environmental & Social Information Classification · 99% confidence The document is titled "MedinCell, société à impact engagée dans l'amélioration de la santé des patients dans le monde, publie son rapport annuel RSE 2021-2022" (MedinCell, an impact company committed to improving patient health worldwide, publishes its 2021-2022 CSR annual report). The text explicitly mentions the publication of the CSR (Corporate Social Responsibility) annual report and provides links to download it. The CSR report aligns directly with the definition of an Environmental & Social Report (ESG/CSR). Although it is an announcement of the report's publication, the core subject matter is the ESG/CSR report itself, which is a specific category (SR). Given the document's focus is detailing the content of the RSE report rather than just announcing its availability (though it does both), SR is the most precise fit over the general RPA or RNS. The length (6710 chars) is substantial enough to suggest it contains more than just a brief announcement header.
2022-08-17 French
Total du nombre de droits de vote et du capital / Information relative au nombre total de droits de vote et d'actions composant le capital
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled "Information mensuelle relative au nombre d'actions composant le capital social et au nombre total des droits de vote" (Monthly information relating to the number of shares comprising the share capital and the total number of voting rights), dated August 8, 2022, and references Article 223-16 of the AMF General Regulation. It explicitly details the total number of outstanding shares and the total gross and net voting rights as of July 31, 2022. This content directly relates to changes in share capital structure and voting rights, which aligns best with the 'Share Issue/Capital Change' (SHA) category, as it reports on the composition of the capital and voting rights, which are fundamental components of share structure reporting. While it touches upon voting rights, it is a routine monthly capital update rather than a specific declaration of voting results (DVA) from a meeting. It is not a general regulatory filing (RNS) because it fits a more specific category.
2022-08-08 French

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.